Skip to main content

01.12.2015 | Research article | Ausgabe 1/2015 Open Access

BMC Urology 1/2015

Survival and prognostic factors for adrenocortical carcinoma: a single institution experience

BMC Urology > Ausgabe 1/2015
Zlatibor Loncar, Vladimir Djukic, Vladan Zivaljevic, Tatjana Pekmezovic, Aleksandar Diklic, Svetislav Tatic, Dusko Dundjerovic, Branislav Olujic, Nikola Slijepcevic, Ivan Paunovic
Wichtige Hinweise

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

ZL made substantial contributions to conception of the study, wrote the paper and has been involved in all steps of the study. VD, VZ and TP made substantial contributions to design of the study, and have been involved in critically revising of the manuscript for important intellectual content. AD, ST, DD, BO, NS and IP have been involved in acquisition of data. All authors read and approved the final manuscript.



Adrenocortical carcinoma (ACC) is aggressive, but rare tumours that have not been sufficiently studied. The aim of our study was to present the demographic and clinical characteristics of patients with ACC, to determine the overall survival rates, analyse the effect of prognostic factors on survival, as well as to identify favorable and unfavourable predictors of survival.


The study included 72 patients (42 women and 30 men) with ACC. We analysed the prognostic value of the demographic and clinical characteristics of the patients, tumour characteristics, therapy administered and survival rates. Kaplan-Meier survival curves and the log-rank test were used to estimate the overall and specific survival probabilities and the Cox regression model was used to identify independent prognostic factors for survival.


The patients had mean age of 50 years. The 1-, 5-, and 10-year probabilities of survival in patients with ACC were 52.5 %, 41.1 %, and 16.4 %, respectively. The median survival time was 36 months. The results of multivariate Cox regression analysis showed that the presence of lymphatic metastases (HR = 7.37, 95 % CI = 2.31-23.48, p = 0.001) and therapy with mitotane (HR = 0.11, 95 % CI = 0.04-0.27, p = 0.001) were independent prognostic factors for survival.


The presence of lymphatic metastasis is an unfavourable prognostic factor, while postoperative therapy with mitotane is a favorable prognostic factor for survival in patients with ACC.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2015

BMC Urology 1/2015 Zur Ausgabe

Neu im Fachgebiet Urologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Urologie und bleiben Sie gut informiert – ganz bequem per eMail.